Stage-by-stage guides
Plain-language guides separate intake, screening, dosing-day observation, discharge, and aftercare questions without presenting any stage as inherently safe.
Follow the centre-stage sequenceIndependent information services
Services
Compact, evidence-aware tools for people trying to understand what may happen inside an ibogaine therapy centre, stage by stage, and what safety questions remain unanswered.
Setting comparison
Risk clarity
Evidence limits
What is available
Information for a difficult decision
These are research and decision-support materials, not clinical services or recommendations about whether ibogaine is appropriate for any person.
Screening questions
Decision frameworks help readers identify what a setting says about medical history, medication review, monitoring, escalation, and transfer planning.
Review risk and screening topicsCentre comparison
Comparison prompts make it easier to distinguish a claim from a documented process and to notice missing detail before relying on a centre’s assurances.
Use the comparison frameworkResearch summaries
Short evidence summaries describe uncertainty, study limits, and why an investigational intervention should not be confused with established medical care.
See how Long Waypoint 3 approaches evidence
Key workflow
A centre is more than the treatment day
-
01
Before arrivalQuestions about eligibility claims, records, medications, travel, and whether exclusions are clearly explained.
-
02
Screening and planningQuestions about what screening is done, who reviews it, and what happens when a concern appears.
-
03
Observation and responseQuestions about the environment, monitoring, staffing, emergency preparation, and escalation pathways.
-
04
Leaving and follow-upQuestions about discharge criteria, support boundaries, continuity, and plans for unexpected difficulties after departure.
Evidence limits
Clarity should not become reassurance
Are these medical services?
No. Long Waypoint 3 is an independent information resource. It does not provide medical care, treatment referrals, diagnoses, or legal advice.
What does a centre-stage guide cover?
It organizes questions about intake, screening, monitoring, observation, discharge, and follow-up so readers can compare what a setting says it provides.
“A useful comparison asks what can be verified, what remains unclear, and what would happen if the situation changes.”
Ibogaine has been associated with serious cardiac risk, which is why the FDA’s ibogaine safety alert is relevant context for any discussion of screening or monitoring claims. A setting’s own language cannot resolve that risk.
Background on the compound can also be separated from claims about outcomes: the overview of ibogaine notes its investigational status and longstanding safety concerns. For a structured starting point, the main guide to evaluating ibogaine settings maps the questions that recur before, during, and after a proposed visit.
Readers wanting to compare public descriptions of different options can use the explanatory material at ibogaine treatment information in the United States, while keeping in mind that information cannot substitute for individualized medical assessment.
Independent resource
Start with the questions, not the promises.
Long Waypoint 3 examines ibogaine as an investigational, medically hazardous intervention and helps readers compare settings with informed caution.